Trendlines Labs is to receive a grant from the Singapore Israel Industrial Research and Development Foundation for the development and clinical trial of its stress urinary incontinence (SUI) product, which is being developed in partnership with the Singapore General Hospital.
The 50 women in the trial, expected to start mid-2017 at the hospital, will provide feedback on the product. The foundation will provide up to 50 percent of the $400,000 the partners need to fund the final product development and clinical trial.
Read more on The Times of Israel here.
![[Ravin in the Jerusalem Post] Ravin AI granted patent for vehicle ‘damage-finder’ system](https://blog.ourcrowd.com/wp-content/themes/Extra/images/post-format-thumb-text.svg)
